Xylem INC

Xylem Inc. announced the appointment of Andrea van der Berg as its new Executive Vice President and Chief Financial Officer, effective September 1, 2026, and reaffirmed its financial guidance for Q3 and full-year 2026.

Xylem Inc. announced the appointment of D. Christian Koch to its Board of Directors, expanding the board to ten members and adding significant leadership experience.

Xylem Inc. announced robust second-quarter 2026 financial results, with significant order growth and improved earnings per share, leading to an upward revision of its full-year guidance.

Xylem Inc. has successfully issued $1 billion in senior notes to refinance existing debt and fund eligible blue projects.

Xylem Inc. announced the results of its 2026 Annual Meeting of Shareholders, with all director nominees elected and key proposals approved.

Xylem Inc. announced first-quarter 2026 financial results, with revenue and orders showing modest growth and earnings per share significantly increasing.

Xylem Inc. announced a 1.5% revenue increase to $2.34 billion for Q2 2026, driven by organic growth and favorable currency impacts, with orders surging 42%.

Xylem Inc. reported a 2.7% increase in first-quarter 2026 revenue to $2.125 billion, driven by favorable foreign currency impacts, with net income attributable to Xylem rising 14.2% to $193 million.

Xylem Inc. reported robust third-quarter 2025 results with significant revenue and earnings growth, driven by organic expansion and margin improvements, leading to an increased full-year outlook.

Xylem Inc. delivered robust financial results for the second quarter of 2025, driven by organic growth and operational efficiencies, leading to an upward revision of its full-year revenue outlook.

Xylem Inc. announces a 1.8% increase in revenue for Q1 2025, driven by organic growth, and maintains its full-year outlook.

Xylem Inc. announced a modest revenue increase of 1.3% in Q3 2024, alongside significant improvements in profitability and adjusted EBITDA margin, while navigating ongoing restructuring efforts.

Xylem Inc. announced robust financial results for fiscal year 2025, with significant revenue and earnings growth driven by organic expansion and strategic acquisitions in the global water technology sector.

Xylem Inc. announces a 16.3% revenue increase in 2024, reaching $8.6 billion, fueled by strategic acquisitions and robust organic growth across key segments.

Xylem's 2023 annual report reveals a significant revenue increase driven by the Evoqua acquisition and strong organic growth across all segments.

D Christian Koch, a Director of Xylem Inc., received 1,247 shares of common stock on August 13, 2026.

Michael J. McGann, EVP & President of MCS at Xylem Inc., reported a stock transaction on July 1, 2026.

Xylem Inc. Director Uday Yadav was awarded 1,711 restricted stock units, aligning his interests with shareholders.

Xylem Inc. Director Lila Tretikov was granted 1,711 restricted stock units valued at $116.88 per share, vesting before the 2027 Annual Meeting.

Director Mark D. Morelli acquired 1,711 restricted stock units of Xylem Inc. as part of an equity incentive plan.

Xylem Inc. Director Robert F. Friel acquired 2,481 shares of common stock via a restricted stock unit award.

Xylem reported record 2025 results and asked shareholders to elect nine directors, ratify Deloitte, approve executive pay, and adopt a 2026 Employee Stock Purchase Plan ahead of its May 14, 2026 virtual annual meeting.

Xylem Inc. will hold its annual meeting on May 13, 2025, where shareholders will vote on the election of directors, ratification of the auditor, executive compensation, and a shareholder proposal regarding special meetings.

Xylem Inc. announces record revenue, profitability, and earnings per share for 2024, driven by the Evoqua acquisition and strategic operational improvements.

Xylem Inc. is holding its annual shareholder meeting on May 16, 2024, to vote on the election of directors, ratification of auditors, and executive compensation.

Xylem Inc.'s 2024 proxy statement highlights a transformational year marked by the acquisition of Evoqua, leadership changes, and strong financial performance, setting the stage for future growth and impact.

Vanguard Capital Management has filed a Schedule 13G reporting beneficial ownership of 7.48% of Xylem Inc. common stock.

The Vanguard Group has filed an amended Schedule 13G, reporting zero beneficial ownership in Xylem Inc/NY common stock following an internal realignment.